Open AccessRaltegravir (RAL) in Neonates: Dosing, Pharmacokinetics (PK), and Safety in HIV-1–Exposed Neonates at Risk of Infection (IMPAACT P1110)
Author(s) -
Diana F. Clarke,
Edward P. Acosta,
Mae Cababasay,
Jiajia Wang,
Anne Chain,
Hedy Teppler,
Stephanie Popson,
Bobbie Graham,
Betsy Smith,
Rohan Hazra,
Kat Calabrese,
Yvonne J. Bryson,
Stephen A. Spector,
Jos Lommerse,
Mark Mirochnick,
Impaact P Protocol Team
Publication year - 2020
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0000000000002294
Subject(s) - raltegravir , dosing , medicine , regimen , cohort , population , pharmacokinetics , pediatrics , cmax , pharmacology , viral load , human immunodeficiency virus (hiv) , immunology , antiretroviral therapy , environmental health
Adequate pharmacokinetic and safety data in neonates are lacking for most antiretroviral agents. Raltegravir is a selective HIV-1 integrase strand transfer inhibitor available in a granule formulation suitable for use in neonates and young infants as prophylaxis or treatment of HIV infection.